CalciMedica: CRACking toxicity

Calcineurin inhibitors are effective in preventing acute organ transplant rejection and treating autoimmune diseases, but their long-term use is associated with renal and hepatic toxicities. CalciMedica Inc. hopes to sidestep these toxicities by developing therapeutics that modulate calcium release-activated calcium channels, key upstream regulators of calcineurin activity.

Both of the calcineurin inhibitors

Read the full 518 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE